Bone Cancer - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 48 pages report, published by Global Markets Direct

Keywords : Bone Cancer Therapeutic Products under Development, Key Players in Bone Cancer Therapeutics, Bone Cancer Pipeline Overview, Bone Cancer Pipeline, Bone Cancer Pipeline Assessment

Report ThumbnailSeptember-2013
Bone Cancer - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Bone Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Bone Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Cancer. Bone Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bone Cancer.
- A review of the Bone Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bone Cancer pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bone Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bone Cancer pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Bone Cancer, H2 2013 7
  • Products under Development for Bone Cancer - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Products under Investigation by Universities/Institutes, H2 2013 10
  • Mid Clinical Stage Products, H2 2013 11
  • Early Clinical Stage Products, H2 2013 12
  • Discovery and Pre-Clinical Stage Products, H2 2013 13
  • Assessment by Monotherapy Products, H2 2013 21
  • Assessment by Route of Administration, H2 2013 22
  • Assessment by Stage and Route of Administration, H2 2013 23
  • Assessment by Molecule Type, H2 2013 24
  • Assessment by Stage and Molecule Type, H2 2013 25
  • List of Tables
  • Number of Products Under Development for Bone Cancer, H2 2013 7
  • Products under Development for Bone Cancer - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Number of Products under Investigation by Universities/Institutes, H2 2013 10
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 11
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 12
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 13
  • Products under Development by Companies, H2 2013 14
  • Products under Investigation by Universities/Institutes, H2 2013 15
  • Debiopharm Group, H2 2013 16
  • Aileron Therapeutics, Inc., H2 2013 17
  • Hawthorn Pharmaceuticals, Inc., H2 2013 18
  • Virobay Inc., H2 2013 19
  • KaloBios Pharmaceuticals, Inc., H2 2013 20
  • Assessment by Monotherapy Products, H2 2013 21
  • Assessment by Stage and Route of Administration, H2 2013 23
  • Assessment by Stage and Molecule Type, H2 2013 25
  • Bone Cancer Therapeutics - Drug Profile Updates 34
  • Bone Cancer Therapeutics - Dormant Products 36
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Bone Cancer Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Bone Cancer 7
  • Bone Cancer Therapeutics under Development by Companies 9
  • Bone Cancer Therapeutics under Investigation by Universities/Institutes 10
  • Mid Clinical Stage Products 11
  • Comparative Analysis 11
  • Early Clinical Stage Products 12
  • Comparative Analysis 12
  • Discovery and Pre-Clinical Stage Products 13
  • Comparative Analysis 13
  • Bone Cancer Therapeutics - Products under Development by Companies 14
  • Bone Cancer Therapeutics - Products under Investigation by Universities/Institutes 15
  • Companies Involved in Bone Cancer Therapeutics Development 16
  • Debiopharm Group 16
  • Aileron Therapeutics, Inc. 17
  • Hawthorn Pharmaceuticals, Inc. 18
  • Virobay Inc. 19
  • KaloBios Pharmaceuticals, Inc. 20
  • Bone Cancer - Therapeutics Assessment 21
  • Assessment by Monotherapy Products 21
  • Assessment by Route of Administration 22
  • Assessment by Molecule Type 24
  • Drug Profiles 26
  • Debio-0719 - Drug Profile 26
  • Product Description 26
  • Mechanism of Action 26
  • R&D Progress 26
  • VBY-825 - Drug Profile 27
  • Product Description 27
  • Mechanism of Action 27
  • R&D Progress 27
  • KB-003 - Drug Profile 28
  • Product Description 28
  • Mechanism of Action 28
  • R&D Progress 28
  • Angiotensin 1-7 - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • ATSP-7041 - Drug Profile 31
  • Product Description 31
  • Mechanism of Action 31
  • R&D Progress 31
  • MN-1 - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • Astrogorgiadiol - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • Bone Cancer Therapeutics - Drug Profile Updates 34
  • Bone Cancer Therapeutics - Dormant Products 36
  • Bone Cancer - Product Development Milestones 37
  • Featured News & Press Releases 37
  • Oct 22, 2012: Eleison Enrolls First Patient In Phase II Trial Of Cisplatin For Pediatric Bone Cancer 37
  • Sep 12, 2012: Indian Supreme Court Asks Novartis To Scale Down Price Of Cancer Drug Glivec 37
  • Aug 07, 2012: Philips And Celsion Announce FDA Clearance To Commence Phase II Study Of ThermoDox And MR-Guided HIFU In Bone Cancer 37
  • Mar 02, 2012: Niiki Pharma To Begin Phase I Trial Of NKP-2235 38
  • Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model 39
  • Jun 22, 2011: Celsion's ThermoDox Featured In Special Issue Of The Open Nanomedicine Journal 39
  • Jun 06, 2011: Merck And ARIAD Announce Presentation Of Results Of Phase III SUCCEED Trial At ASCO Annual Meeting 41
  • Jul 11, 2007: Amgen and Daiichi Sankyo Announce Agreement For Denosumab In Japan 42
  • Mar 14, 2002: Amgen Signs Multi-Year Agreement With International Oncology Network for Aranesp, Neulasta and NEUPOGEN 43
  • Mar 14, 2002: Amgen Signs Multi-Year Agreement With US Oncology for Aranesp, Neulasta and NEUPOGEN 45
  • Appendix 47
  • Methodology 47
  • Coverage 47
  • Secondary Research 47
  • Primary Research 47
  • Expert Panel Validation 47
  • Contact Us 48
  • Disclaimer 48

Please select a license type

Share

Related Products

Global Markets DirectBone Cancer - Pipeline Review, H2 2013Product ThumbnailBone Cancer - Pipeline Review, H2 2013, Industry ReportProduct #: 113326
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved